Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:14 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 12,512 matching trials from the live ClinicalTrials.gov search.
Filters: Miami, Florida Clear all
Completed Phase 3 Interventional

Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00023972
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
exatecan mesylate, gemcitabine hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
66
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional Results available

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

NCT05901831
View directory record Official record
Conditions
Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions
Finerenone, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Surprise, Arizona • Stanford, California • Vallejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 2, 2026, 5:14 PM EST
Not yet recruiting Phase 2 Interventional

FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma

NCT07609472
View directory record Official record
Conditions
High-Grade Glioma (WHO III-IV)
Interventions
FG001
Drug
Lead sponsor
FluoGuide A/S
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Miami, Florida • Lebanon, New Hampshire • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 2, 2026, 5:14 PM EST
Available No phase listed Expanded access

Rescue of Infants With MCT8 Deficiency

NCT04143295
View directory record Official record
Conditions
Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency
Interventions
Diiodothyropropionic acid (DITPA)
Drug
Lead sponsor
Roy E. Weiss, M.D.
Other
Eligibility
Up to 18 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

NCT00017719
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
44
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 2, 2026, 5:14 PM EST
Withdrawn Not applicable Interventional

Transoral Gastric Volume Reduction as an Intervention for Weight Management

NCT02578836
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Fogel Gastroplasty
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Nov 2, 2026, 5:14 PM EST
Completed Not applicable Interventional Results available

Visual Restoration for Hemianopia

NCT03350919
View directory record Official record
Conditions
Stroke Induced Vision Loss, Hemianopia, Quadrantanopia
Interventions
Training in the blind field, Training in the intact field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 2 Interventional Results available

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

NCT05771428
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-552, Placebo for ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 2 Interventional

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

NCT00031967
View directory record Official record
Conditions
Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic melatonin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
215
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 2 Interventional Results available

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00108953
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 4 Interventional

A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers

NCT01327937
View directory record Official record
Conditions
Venous Ulcer
Interventions
Apligraf, Standard of Care Dressing Group
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

NCT03310957
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
ladiratuzumab vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

NCT05822830
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Active, not recruiting Phase 1 Interventional

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT03860272
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

NCT00449501
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
46
States / cities
Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Nov 2, 2026, 5:14 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional Results available

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

NCT02336230
View directory record Official record
Conditions
Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
Interventions
remestemcel-L
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Nov 2, 2026, 5:14 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457
View directory record Official record
Conditions
Episodic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 2, 2026, 5:14 PM EST
Completed Not applicable Interventional Results available

Intervention to Retain HIV-positive Patients in Medical Care

NCT01537367
View directory record Official record
Conditions
Primary Care Appointment Keeping
Interventions
Enhanced contact plus behavioral skills, Enhanced contact only, Standard of Care
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Nov 2, 2026, 5:14 PM EST
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.

NCT05592002
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Genio System
Device
Lead sponsor
Nyxoah S.A.
Industry
Eligibility
22 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Completed No phase listed Observational

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

NCT00001137
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
5,982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Nov 2, 2026, 5:14 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

NCT05763875
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 2, 2026, 5:14 PM EST
Completed Not applicable Interventional

Reducing Obesity Health Disparities in Hispanic Youth

NCT03943628
View directory record Official record
Conditions
Overweight, Family Relations, Adolescent Behavior, Drug Use, Sexual Behavior
Interventions
Familias Unidas
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Years to 15 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Nov 2, 2026, 5:14 PM EST